Michael Erman

Michael Erman is a reputable journalist who specializes in health and science reporting. He has a track record of providing accurate and timely information on various topics, including pharmaceutical developments and clinical trials.

94%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

85%

Examples:

  • In the article 'Pfizer, BioNTech flu-COVID shot shows promise in early data', there is a bias towards highlighting the positive aspects of the trial results, with less emphasis on potential risks or drawbacks.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

Meta-Analysis Reveals Early Use of Antivirals Reduces Long COVID Risk by 23%: Further Research Needed

Meta-Analysis Reveals Early Use of Antivirals Reduces Long COVID Risk by 23%: Further Research Needed

Broke On: Saturday, 08 June 2024 A meta-analysis of nine studies found that early use of antiviral drugs like Paxlovid and molnupiravir reduces the risk of long COVID by 23%. However, a recent Stanford University study failed to show significant benefits for Paxlovid in reducing long COVID symptoms. Further research is needed to determine antivirals' effectiveness. Long COVID, characterized by fatigue, brain fog, and other symptoms lasting weeks or months after infection, may be prevented with early antiviral intervention.

Pfizer and BioNTech Initiate Phase 3 Trial for Combination COVID-19 and Flu Vaccine

Broke On: Thursday, 26 October 2023 Pfizer and BioNTech have started a Phase 3 trial for a combination COVID-19 and flu vaccine. The vaccine uses mRNA technology and aims to simplify the vaccination process. The trial's announcement has led to mixed reactions in the stock market.